BsAbs are classified into two types: those that bear an Fc region and those that lack it.70 Blinatumomab was the first FDA-approved bispecific antibody (bsAb) targeting CD19 on tumor cells and CD3+ cytotoxic immune T cells.71 In 2021, Amivantamab targeting EGFR/METR was approved.72 Here, EGFR is linked to neoplasm.